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Systemic lupus erythematosus (SLE; OMIM 152700) is a genetically complex 46 
autoimmune disease. Over 50 loci have been found to be robustly associated by 47 
GWAS in single ethnicities. We combined three GWAS’ datasets from two ethnicities: 48 
Chinese (1,659 cases and 3,398 controls) and European (4,036 cases and 6,959 49 
controls). A meta–analysis of these studies found that over half of the published SLE 50 
genetic associations are present in both populations. A replication study in the 51 
Chinese (3,043 cases and 5,074 controls) and Europeans (2,643 cases and 9,032 52 
controls) found 10 novel SLE loci. Our study reveals further evidence that the majority 53 
of genetic polymorphisms exerting risk for SLE are contained within the same regions 54 
across the Chinese and European populations. Furthermore, comparing risk allele 55 
frequencies and genetic risk scores suggests that the increased prevalence of SLE in 56 
non–Europeans (including Asians) has a genetic basis.    57 
SLE is a highly complex disease, with occurrence heavily influenced by genetics 58 
(heritability=66%1). SLE incidence varies markedly across populations, with Europeans 59 
showing 34 fold lower prevalence compared with individuals of African or Asian ancestry2. 60 
In recent years, our understanding of SLE genetic aetiology has been transformed by 61 
GWAS, with the largest study in Europeans (4,036 cases and 6,959 controls)3 finding 62 
evidence of association at 41 autosomal loci. Meanwhile, there have been two published 63 
GWAS4,5 in Chinese populations and follow up studies in Asians6-10 that found association at 64 
31 loci, 11 of which are not published in Europeans. Thus 52 SLE disease susceptibility 65 
autosomal loci have been mapped by GWAS in these two populations.  66 
While fine mapping of a selected number of known SLE associated loci11-13 has been 67 
successfully undertaken by combining genetic results obtained from association mapping in 68 
different populations, to date transancestral approaches have not been employed at 69 
genome-wide level in SLE. Studies of other diseases14 have also shown the benefit of 70 
comparing data from differing ancestries to exploit differences in LD.  71 
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Our initial objective was to compare observed genetic association signals across the 72 
genome in Chinese and Europeans. To provide additional power to identify potentially novel 73 
SLE associated loci we imputed each GWAS [A European study: 4,036 cases and 6,959 74 
Controls3 (ȜGC=1.16 with Ȝ1,000=1.02); a study from Anhui province in mainland China: 1,047 75 
cases and 1,205 Controls4 (ȜGC=1.05) and a study from Hong Kong: 612 cases and 2,193 76 
Controls5,7 (ȜGC=1.04)] to the density of the 1000 Genomes (1KG) data (see Online 77 
Methods). Analyses of association results in each population suggested that SLE 78 
susceptibility loci were shared extensively. Manhattan plots showing these similarities are 79 
presented in Fig. 1, where it can be seen that the association signals are mostly mirrored 80 
between populations. Details of the association data for individual SNPs are presented in 81 
Supplementary Table 1. Comparing the published genome-wide significant allelic 82 
associations in SLE, we see that many of the alleles hitherto thought to be associated with 83 
SLE in only one population have evidence for association in both European and Chinese 84 
SLE. Ranking genomic regions based on strength of association, we also find a significant 85 
correlation (P=2.7×109, Kendalls Tau=0.08, see methods) between the two populations 86 
GWAS. These observations suggested that combining GWAS data in a metaanalysis would 87 
likely yield novel association signals. Fig. 1b shows a Manhattan plot of the GWAS meta88 
analysis results, which included three associations in novel loci (rs17603856 6p23; 89 
rs1887428 [9p24]; rs669763 [16q13]) with genome wide level of significance (P<5×1008).  In 90 
addition, it can be seen in this Figure that the Major Histocompatibility Complex (MHC) and 91 
to a lesser extent the IRF5 locus on chromosome 7, exhibit significant transancestral 92 
heterogeneity. 93 
We then carried out a twostage replication study, incorporating rs17603856, rs1887428 and 94 
rs669763. The 1KG-imputed data were scanned for association at loci independent of those 95 
previously published and excluding the MHC. A total of 66 SNPs at 56 loci (Online Methods 96 
describes SNP selection) were successfully genotyped in a further 3,043 cases and 5,074 97 
controls of Chinese ancestry recruited from Anhui Province. Eighteen of these SNPs (at 17 98 
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independent loci) showed association in this replication study, passing a false discovery rate 99 
(FDR) of 0.01. These included rs17603856 and rs1887428 but not rs669763, which failed 100 
quality control. We then genotyped these 18 SNPs in a European replication cohort, 101 
comprising 1,478 cases and 6,925 controls3. Data from an additional EuropeanAmerican 102 
GWAS (1,165 independent cases and 2,107 controls) were also included in this final 103 
analysis15 (Supplementary Table 2a). Of the 18 candidate SNPs, 11 passed a standard 104 
genomewide level of significance (P<5×1008) in the combined meta-analysis (11,381 105 
cases and 24,463 controls) of all three main GWAS and the three replication studies (Table 106 
1; forest plots are presented in Supplementary Fig. 1). The strongest association signal 107 
following this meta-analysis was rs1887428 (9p24). Additional statistically significant 108 
associations were found at rs34889541 (1q31.3), rs2297550 (1q32.1), rs6762714 (3q28), 109 
rs17603856 (6p23), rs597325 (6q15), rs73135369 (7q11.23), rs494003 (11q13.1) and 110 
rs1170426 (16q22.1), while two SNPs at 2p23.1 (rs1732199 and rs7579944) were replicated 111 
as being independently associated (see Online Methods and Table 1). The full set of results 112 
for the 18 candidate markers can be seen in Supplementary Table 2.   113 
In order to highlight potential causal genes at the ten newly described susceptibility loci, the 114 
associated SNPs at each locus were tested for correlation with cisacting gene expression 115 
in ex vivo naïve CD4+ T cells and CD14 monocytes in both Asian and European population 116 
data16, and B cells, T cells and monocytes (stimulated and naïve) in Europeans only17. We 117 
calculated Regulatory Trait Concordance (RTC) scores18 (see Online Methods) to test the 118 
relationship between eQTLs driven by disease-associated alleles, and other, potentially 119 
stronger eQTLs, which we identified at each locus. Supplementary Table 3 and 120 
Supplementary Fig. 2 present results for this analysis in all cell types in circumstances where 121 
eQTLs were found in at least one cell type/population. The eQTLs were consistent across 122 
cell type and population for LBH (rs19991732), CTSW (rs494003), RNASEH2C (rs494003) 123 
and ZFP90 (rs1170426), with carriage of the SLE risk allele correlating with reduced 124 
expression (except in LPS stimulated monocytes for RNASEH2C where the eQTL results 125 
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were not significant and the RTC scores were very low). The SNP rs2297550 was found to 126 
be an eQTL for IKBKE with the SLE risk allele correlated with reduced expression in T cells, 127 
IFN stimulated monocytes, B cells and NK cells, but increased expression in monocytes.  128 
We integrated the results of the eQTL analyses with an in silico survey of murine phenotype 129 
data resulting from knockouts of genes within the associated SLE loci (Table 2)19-28. These 130 
lines of evidence point to one likely causal gene at some loci, IKBKE and JAK2 for example. 131 
In other instances, we found evidence that supports the role of multiple genes as candidates 132 
at a given locus; for example, CTSW / RNASEH2C and CDH1 / ZFP90. Locus Zoom29 plots, 133 
using the European and meta-analysed Chinese data, for all 10 loci can be seen in 134 
Supplementary Fig. 3, which facilitate a comparison of the alignment of the association 135 
signals in the two populations. The potential roles of the putative causal genes at the loci 136 
mapped in this study are described in Supplementary Table 4. 137 
The level of shared association we noted in our initial combination of the two ethnicities 138 
GWAS was exploited further using fine mapping analyses of all published associated loci 139 
(Supplementary Table 1) and the loci we present as novel in this paper. We derived 140 
Bayesian credibility sets (C.S.) in each population for the most likely causal variants using a 141 
previously published approach30-32. We report the intersection of these sets (see methods) 142 
and Supplementary Fig. 4 displays the observed cumulative distribution for the number of 143 
SNPs in the intersection over a range of levels. Using the least stringent criterion (75% 144 
C.S.), 80% of the mapped loci had sets identifying 10 or less likely causal SNPs. Using a 145 
very rigorous criterion (99% C.S.), seven of the loci comprised less than 10 SNPs 146 
(Supplementary Table 5). STAT4 is a good example of the colocalisation of signals from 147 
each ancestry, which we show in detail in Fig. 2. In contrast we show two examples in the 148 
Figure where the association arises in one population only: IRF7 (European) and ELF1 149 
(Chinese). In each case it is evident that the likely explanation for the discrepant association 150 
signal is population-specific allele frequency differences within the credible SNP set. 151 
Supplementary Fig. 5 displays fine mapping data for the novel loci. 152 
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We downloaded epigenetic data covering each of the novel 10 associated loci identified by 153 
the meta-analysis (Table 1) from the RoadMap consortium for all blood cell types33. This was 154 
performed for all SNPs within the C.S. at each locus. Fig. 3 displays the results for SNPs at 155 
three loci, showing the level of RNA expression (RNAseq), accessibility to DNAse, histone 156 
modification by acetylation (H3K27ac, H3K9ac) and histone modification by methylation 157 
(H3K27me3, H3K9me3). Supplementary Fig. 6 displays results for the other seven SNPs. 158 
The histone marks were selected to indicate the activation status of promoter and enhancer 159 
regions and regions of repression. This epigenetic annotation provides an interesting point of 160 
comparison with the eQTL results. Two intense histone acetylation peaks were observed 161 
around the associated SNPs rs2297550 (IKBKE) and rs1887428 (JAK2), yet only the variant 162 
in IKBKE showed a significant eQTL in the cells examined. Although we did find a significant 163 
eQTL for rs1887428 with JAK2 in monocytes, the RTC scores were low (<0.4). At SNPs, 164 
rs34889541 (CD45) and rs597325 (BACH2), there was local evidence of histone acetylation 165 
in lymphocytes, but the two SNPs were not significant eQTLs. In contrast, rs1170426 166 
(ZFP90) was a very significant eQTL, but the region around the associated SNP showed 167 
little evidence of regulatory function. However there was strong evidence of epigenetic 168 
effects at other SNPs contained in the ZFP90 C.S.  Some of the discrepancies between 169 
eQTL and epigenetic annotation likely represent the limited set of activation states (and 170 
perhaps samples sizes) of primary immune cells that have been subject to eQTL 171 
investigation. 172 
The amount of shared risk effects between the Chinese and European populations was 173 
further investigated with a co-heritability analysis using LD score regression34 (see methods) 174 
which showed a significant (P=4.0×1003, rg=0.51) correlation between the two populations, 175 
with this correlation being stronger (P = 4.88 × 1005, rg=0.62) after removing the MHC which 176 
emphasises its heterogeneity (Fig. 1b). These results beg the question: does the higher 177 
prevalence of SLE in Asians (compared with Europeans) have a genetic basis? We 178 
observed that on average the risk allele frequencies (RAF) in Chinese were significantly 179 
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higher than those in Europeans in the respective GWAS controls (paired ttest, P=0.02, 180 
Supplementary Fig. 7a) while the effect sizes (ORs) were not statistically different (P=0.47, 181 
Supplementary Fig. 7b). We also compared the genetic risk scores (GRS)  the joint effect 182 
of ORs and RAFs  between populations in data from 1KG (Phase III) (Fig. 4) and between 183 
the Chinese and European GWAS controls (Supplementary Fig. 8a). The GRS for SLE in 184 
East Asians (EAS) was significantly higher than that in Europeans (EUR) in the 1KG data 185 
[fold (EAS/EUR)=1.27, P=4.99×10179; EUR=7.38 95%C.I. 7.317.45; EAS=9.35, 95%C.I. 186 
9.279.43]. There was a similar difference in score between the GWAS controls [fold 187 
(Chinese/European) = 1.28, P=1.00×10797; European=7.42, 95%C.I. 7.407.44; 188 
Chinese=9.51 95%C.I. 9.469.55]. With more associations to be identified in future studies, 189 
especially with increased power in non-European populations including East Asians, the 190 
difference in genetic predisposition between populations revealed by GWAS might further 191 
increase. We note that an analyses of chip heritability (using all genotyped SNPs to calculate 192 
heritability explained, see methods) in both the CHN and EUR data resulted in 28% 193 
(s.e.=2.6%) explained in CHN and 27% (s.e.=1.0%) explained in EUR. 194 
Furthermore, we see a correlation between the GRS across all five major 1KG super195 
populations and rank of the prevalence2 (see methods) of SLE (Fig. 4). A ttest on mean 196 
GRS between each pair of population data was highly significant (P<1016) for all pairs 197 
except AMR versus SAS (P=0.67) and a linear model with rank of prevalence predicting the 198 
GRS was significant (P<1016, r2=0.39). We have excluded the MHC from this analysis due 199 
to the difficulty of defining the best model of association in this region, due to the extensive 200 
LD and limited genotyping of SNPs and classical HLA in both populations.  201 
The increased genetic load in Chinese would help explain the continued increased 202 
prevalence in Asians following migration to Western locations2. We acknowledge that the 203 
trends we observe are a snapshot, as all available genotyped SNPs explained <30% 204 
disease heritability, and the comparison of GRS may not be a full reflection of genetic risk 205 
amongst the populations. A more detailed study of the increased prevalence of SLE in 206 
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Asians, and Africans, will require extensive comparisons of genetic and environmental data, 207 
including generation of DNA sequence data to exclude the European bias in genotyping 208 
arrays. 209 
URLs. Department of Twin Research, Kings College London, TwinsUK samples, 210 
http://www.twinsuk.ac.uk; Ingenuity Pathway Analysis, http://www.ingenuity.com/; 211 
Immunobase, http://www.immunobase.org. Systems Biology and Complex Disease 212 
Genetics, http://insidegen.com.  213 
RoadMap data (http://egg2.wustl.edu/roadmap/data/byFileType/signal/consolidatedImputed/ 214 
 215 
Data Access 216 
All 1KG imputed summary statistics are available at http://insidegen.com/insidegenLUPUS217 
data.html  218 
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Figure Legends 389 
Figure 1 (a) Manhattan plot of the European and Chinese (meta-analysis of two Chinese 390 
GWAS) GWASs. The log10 P-values for Europeans are shown in light blue with the log10 P–391 
values for the Chinese in pink. The 52 loci with published evidence of association are 392 
highlighted in blue and red while the 10 novel loci indented as associated from this study are 393 
highlighted in black. (b) Log10 P-values for meta-analysis (Europeans combined with 394 
Chinese GWAS) in grey with the log10 P-values for a test of heterogeneity between the 395 
European and Chinese GWAS in brown. The 52 loci with published evidence of association 396 
are highlighted in black (meta P-values) and dark brown (heterogeneity test) while the 10 397 
novel loci indented as associated from this study are highlighted in black.  398 
 399 
Figure 2 Fine mapping examples for STAT4, IRF7 and ELF1. The upper plots are 400 
LocusZoom plots showing association significance [log10(P-value)] and local LD (colour 401 
coded). Circular points represent SNPs contained within the credibility sets and square 402 
points represent SNPs not contained in the sets. The lower plots display the minor allele 403 
frequencies (MAF) for all the SNPs in the intersection of the European (EUR) and Chinese 404 
(CHN) credibility sets. The MAF is plotted in red. The SNPs with highest posterior probability 405 
within the intersection of C.I.s are highlighted in BLUE (highest posterior probability in the 406 
EUR data), RED (highest posterior probability in the CHN data) and BLACK (highest 407 
posterior probability in the CHN-EUR Meta data). The C.S. coverage (99% for STAT4, 90% 408 
for IRF7 and ELF1) was chosen as the maximum coverage that included a maximum of 30 409 
SNPs.  410 
Figure 3 3D enrichment plots depict epigenetic modifications +/50bp overlapping all SNPs 411 
in the Credibility Sets for the 11 novel associated SNPs.  The SNPs are shown as individual 412 
tracks on the x-axis with the SNP used in the replication study marked (*) and the SNP that 413 
shows the best evidence for co-localisation with the most prominent epigenetic mark (#).  414 
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Other SNP identities are listed in Supplementary Table 6.  The zaxis represents log10 P-415 
value against the null hypothesis that peak intensity arises from the control distribution. The 416 
z-axis is truncated at a lower level of (P<1004). Each novel associated locus has a separate 417 
panel with results for RNA expression (RNA-seq), accessibility to DNAse, histone 418 
modification by acetylation (H3K27ac, H3K9ac) and histone modification by methylation 419 
(H3K27me3, H3K9me3) over 27 immune cells. The data from the blood cell types are 420 
consistently ordered on the y-axis according to the annotation to the right of the figure: 421 
categories 19 innate response immune cells; categories 1024 adaptive response immune 422 
cell types (categories 1011 B-cells; categories 1224 T-cells) and then categories 2527 423 
cell lines.  424 
 425 
Figure 4 Box plots of genetic risk score (GRS) for across the five major population groups. 426 
These are standard box plots with medians, interquartile ranges and whiskers at 1.5 of the 427 
interquartile range (Tukey box plots) displayed. (EUR European N=498, AMR Amerindian 428 
N=347, SAS South Asian N=487, EAS East Asian N=503, AFR African N=657) in the 1,000 429 
Genomes phase III release.  The dotted line represented the increase in prevalence with the 430 




Table 1: Summary of statistical associations for new loci 
SNP Chr Position Risk 
allelea Chinese MAF
b















    
Case Control Case Control OR (95% CI)c P 
OR 
(95% CI) P 
OR 
(95% CI) P   
rs34889541 1q31.3 198,594,769 G 0.126 0.14 0.058 0.07 
0.78 
(0.72  0.84) 
2.96E10 
0.86 
(0.79  0.94) 
5.34E04 
0.81 
(0.76  0.86) 
2.44E12 
PTPRC 
(CD45) MS, RA, T1D 
rs2297550 1q32.1 206,643,772 G 0.577 0.546 0.14 0.12 
1.14 
(1.08  1.20) 
1.73E07 
1.18 
(1.09  1.27) 
1.43E05 
1.16 
(1.11  1.21) 
1.31E11 IKBKE 
 
rs7579944 2p23.1 30,445,026 C 0.59 0.641 0.338 0.366 
0.87 
(0.82  0.92) 
5.52E06 
0.92 
(0.88  0.96) 
3.96E05 
0.90 
(0.87  0.93) 
1.41E09 LBHe 
RA, AA, IBD, 
NAR, PSC, 
SJO, SSC, VIT 
rs17321999 2p23.1 30,479,857 C 0.16 0.164 0.161 0.191 
0.82 
(0.77  0.88) 
9.55E09 
0.84 
(0.79  0.89) 
2.26E09 
0.83 
(0.79  0.87) 
2.22E16 LBHe 
RA, AA, IBD, 
NAR, PSC, 
SJO, SSC, VIT 
rs6762714 3q28 188,470,238 T 0.848 0.825 0.421 0.392 
1.20 
(1.12  1.29) 
5.56E07 
1.14 
(1.09  1.19) 
7.97E10 
1.16 





ATD, CEL VIT 
rs17603856 6p23 16,630,898 T 0.221 0.222 0.325 0.355 
0.86 
(0.80  0.92) 
1.61E05 
0.89 
(0.85  0.93) 
3.34E08 
0.88 
(0.85  0.91) 
3.27E12 ATXN1 
 
rs597325 6q15 91,002,494 G 0.485 0.52 0.357 0.385 
0.84 
(0.80  0.89) 
1.05E10 
0.92 
(0.88  0.96) 
2.65E04 
0.89 
(0.86  0.92) 
4.03E12 BACH2 
AS, ATD, CEL, 
CRO, MS, T1D 
IBD, PSC, VIT 
rs73135369 7q11.23 73,940,978 C 0.107 0.076 0.028 0.022 
1.38 
(1.26  1.51) 
7.33E13 
1.20 
(1.05  1.38) 
9.00E03 
1.32 




rs1887428 9p24 4,984,530 G 0.372 0.346 0.398 0.373 
1.24 
(1.17  1.31) 
4.49E14 
1.11 
(1.06  1.16) 
1.25E06 
1.16 
(1.12  1.20) 
2.19E17 JAK2 CRO, UC IBD, PSC, VIT 
rs494003 11q13.1 65,542,298 A 0.116 0.117 0.213 0.19 
1.16 
(1.06  1.27) 
8.38E04 
1.13 
(1.07  1.19) 
1.68E06 
1.14 
(1.09  1.19) 
5.81E09 RNASEH2C CRO, IBD 
rs1170426 16q22.1 68,603,798 C 0.198 0.176 0.252 0.235 
1.20 
(1.12  1.28) 
4.36E08 
1.06 
(1.02  1.10) 
3.59E03 
1.12 
(1.08  1.17) 
2.24E08 ZFP90 MS, UC IBD, PSC, VIT 
Chinese comprises the two Chinese GWAS (1,659 cases and 3,398 controls) and the Chinese Replication (3,043 cases and 5,074 controls). European comprises the European GWAS (4,036 cases and 6,959 controls), the 
additional European GWAS (1,165 cases and 2,107 controls) and the European replication study (1,478 cases and 6,925 controls) 
a
 The risk allele refers to the effect in the overall meta-analysis 
b
 MAF refers to the frequency of allele that is minor in Europeans. 
c
 The Odds Ratio (OR) is with respect to the minor allele.  
d
 For the rationale for candidate gene selection at the associated loci see Table 2 
e
 C6orf1 is also known as LBH, but we chose LBH as our gene because there are two separate signals in LBH. rs7579944 and rs17321999 were found to be independently associated with SLE (see Online Methods): 
rs17321999 was significant (Chinese P = 2.62 x 10
11
; European P = 6.14 x 10
6
; Meta P = 3.33 x 10
15
) when using rs7579944 as a covariate in logistic regression, and rs7579944 was significant (Chinese P = 1.38 x10
8
; 
European P = 4.49 x 10
6
; Meta P = 4.16 x 10
13
) at meta-analysis when using rs17321999 as a covariate in logistic regression. The LD between these two SNPs was very weak in all studies (The r
2
 was as follows in each data 




 Association for the gene(s) implicated by each SNP in other autoimmune diseases (excluding SLE) in Immunobase (www.immunobase.org)  Type 1 diabetes (T1D), Celiac disease (CEL), Multiple Sclerosis (MS), Crohns 
Disease (CRO), Primary Billiary Cirrhosis (PBC), Psoriasis (PSO), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC), Ankylosing Spondylitis (AS), Autoimmune Thyroid Disease (ATD), Juvenile Idiopathic Arthritis (JIA), Alopecia 
















Table 2: Candidate Genes at SLE Associated Loci in MetaAnalysis 
 Associated 
SNP 
Chr Genes within +/200kb of SNP 
Genes within same 








Cis eQTLs with 
SNP 
Likely Causal Gene at Locus 
(Reference) 




SRGAP2, SRGAP2D, IKBKE, RASSF5, 




2 YPEL5, LBH, LOC285043, LCLAT1 LBH  LBH LBH21 
rs6762714
 
3 LPP, TPRG1–AS1 LPP    
rs17603856 6 ATXN1 ATXN1    
rs597325
 
6 BACH2 BACH2 BACH2  BACH222,23  
rs73135369
 
7 CLIP2, GTF2IRD1, GTF2I, LOC101926943 GTF2IRD1   GTF2IRD1/GTF2I24 




EHBP1L1, KCNK7, MAP3K11, PCNXL3, 
SIPA1, RELA, KAT5, RNASEH2C, AP5B1, 
OVOL1, OVOL1–AS1, SNX32, CFL1, 
MUS81, EFEMP2, CTSW, FIBP, CCDC85B, 
FOSL1, 











16 SMPD3, ZFP90, CDH3, CDH1 ZFP90, CDH3 CDH1 ZFP90 ZFP90 (FIK)28 
 
a 
The LD block is defined as SNPs showing a correlation (r
2
) of 0.75 with the associated SNP  
b







ONLINE METHODS 468 
Study design in brief  469 
We combined summary genome wide association data from two Chinese GWAS4,5 [Anhui 470 
province, mainland China: 1,047 cases (63 males) and 1,205 Controls (673 males), ȜGC = 471 
1.05; Hong Kong: 612 cases (50 males) and 2,193 Controls (919 males),ȜGC = 1.04] and a 472 
European GWAS [4,036 cases (365 males) and 6,959 Controls (2,785 males), ȜGC = 1.16 473 
with Ȝ1,000 = 1.02], after imputing all three studies to the 1000 Genome (1KG) data density, 474 
and performed a metaanalysis. As the European data comprise 70% of both total cases 475 
and total controls, and was therefore the driving force in this metaanalysis, we selected 476 
SNPs for replication in a further set of Chinese samples first. We identified a subset of SNPs 477 
in the Chinese replication that passed an FDR of 1% to take forward for replication in 478 
European samples. We then performed replication using a second European GWAS15 479 
independent of our main European GWAS and also de novo genotyping in a new data 480 
cohort of European ancestry. 481 
 482 
Imputation  483 
We pre-phased each of the three studies separately using SHAPEIT35. The studies were 484 
then separately imputed  (IMPUTE36) with 1KG reference data (Phase-I integrated set March 485 
2012 build 37). The three datasets were aligned and meta-analyzed using R37 by the Kings 486 
College London group and also independently by the groups at Anhui and Hong Kong using 487 
METAL38. SNPs with imputation INFO scores < 0.7 in any of the three studies were removed 488 
from further analysis.  The number of SNPs available pre- and post-QC, per chromosome 489 
and per associated locus are displayed in Supplementary Tables 7a and 7f respectively. A 490 
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summary of INFO scores and imputation cross validation are in Supplementary Tables 7be 491 
for each chromosome and Supplementary Tables 7gj for each associated locus. 492 
See supplementary note 3 for a discussion of the limitation of using imputed data.  493 
Statistical analysis 494 
Association testing: Following Imputation, each GWAS dataset was analysed for 495 
association (SNPTEST36), fitting an additive model. We used the inverse variance method 496 
for metaanalysis, combining data from the three studies for SNPs with an imputation INFO 497 
score > 0.7 in all three studies. 498 
Testing for heterogeneity: We tested for heterogeneity between the associations signals in 499 
the Chinese and European data using Cochrans Q statistic (1 degree of freedom in this 500 
case). The P-values on the log10 scale are plotted in Fig. 1b. QQ-plots (one per 501 
chromosome) for the heterogeneity P-values can be seen in Supplementary Fig. 9a and 502 
Bland-Altman plots for differences in genetic effect (log odds-ratio) estimates are in 503 
Supplementary Fig. 9b. 504 
Assessment of shared association between ancestries: To assess the extent to which 505 
genetic association with SLE was shared between the Chinese and European populations, 506 
we compared association results in the European GWAS3 with a metaanalysis of both 507 
Chinese GWAS, for SNPs published as associated in Europeans3 and/or Chinese studies4,6-508 
9. Association signals were declared as shared between the Chinese and Europeans if the 509 
SNP passed any one of the following four tests: 510 
1: the locus had a published association in both Chinese and European studies at a 511 
genomewide level of significance (P < 5 × 1008); 512 
2: the SNP was only published in Europeans but the association P-value in the Chinese 513 
metaanalysis was significant (FDR < 0.01 across all SNPs in this group) and the direction 514 
of effect in all three GWAS was the same.  
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3: the SNP was only published in a Chinese study but the association P-value in the 516 
European GWAS was significant (FDR < 0.01) and the direction of effect in all three GWAS 517 
was the same. 518 
4: If the SNP failed either of tests 2 or 3, we performed a genebased test (applying the 519 
software KGG39-41) on genes within +/1Mb of the published SNP. The locus was deemed 520 
shared if the gene-based P-value was significant at the 0.01 level after adjusting for multiple 521 
testing across all genes tested.  522 
We also performed a meta-analysis (European GWAS + both Chinese GWASs) of all loci 523 
published in either Chinese or European studies (each published SNP +/1Mb) and 524 
recorded the most associated SNP. For loci published in Europeans, we declared the loci 525 
shared if the P-value (adjusted for multiple testing over all SNPs tested within the 2Mb 526 
region) in the Chinese data passed an FDR at 0.01 across all the loci published only in 527 
Europeans. We performed the reverse test for all loci published only in Chinese. While this 528 
did not identify any further shared loci (Supplementary Table 1b), two loci showed 529 
suggestive evidence (P < 0.05 after multiple testing adjustment within loci but not after 530 
adjusting across loci.) 531 
Consistency of association between ancestries: We tested the hypothesis that the 532 
genomewide association signals were consistent between the two populations. Post 1KG 533 
imputed association data were used for SNPs with INFO > 0.7. These genome wide 534 
association signals were separated into 1Mb regions (moving 1MB windows across the 535 
genome, 2,698 in total). We removed the extended MHC with a conservative buffer zone 536 
(Chr6, from 20Mb to 40Mb), leaving 2,678 regions. We also removed regions that had 537 
excessively (more than 2 standard deviations from the average) low (N < 1000) or high (N > 538 
3000) density of SNPs. This removed only 10% of the regions, leaving 2,338 regions. The 539 
lowest P-value within each window was taken as the strength of association for that 540 
particular window. Each P-value within each region was adjusted for multiple testing using a 541 
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Bonferroni adjustment, to avoid bias in ranking agreement owing to the lowest Pvalue being 542 
correlated with the number of statistical tests. The 1Mb regions within each populations data 543 
were then ranked according to the P-value (lowest P-value having rank 1). We tested 544 
agreement in ranking using Kendalls Tau statistic. Supplementary Fig. 7ci shows a heat 545 
map of the ranks [red for highest rank (lowest P-value) and blue for lowest rank (highest P-546 
value)] for all 2,338 regions. The order in this heat map was determined by the sum of the 547 
ranks (the region at the top of the figure has the smallest rank sum across the two 548 
populations). European ranks were plotted next to the Chinese ranks. For comparison, a 549 
simulated ranked dataset is shown alongside; we permuted the numbers 1 to 2,338 in two 550 
separate datasets and produced a heat map ordered by the sum of the ranks. 551 
Supplementary Fig. 7cii shows the same data but only for the top 250 regions. 552 
Supplementary Fig. 7ciii shows the top 50 regions. 553 
Testing for independent effects within loci: We tested for independent effects of the two 554 
SNPs (rs17321999 and rs7579944) within the 2p23.1 locus by fitting a multiple regression 555 
model with both SNPs as explanatory variables (results for each SNP in this analysis are 556 
conditional on the other SNP as a covariate). We checked linkage disequilibrium between 557 
the two SNPs in all datasets. The conditional results were combined in meta-analysis in the 558 
same way as the singlemarker analysis. 559 
Selection of SNPs for replication study: SNPs were chosen for replication in the Chinese 560 
samples using a number of criteria. We only chose SNPs that were not within a 1Mb window 561 
of loci that had previously been published as associated with SLE. We selected SNPs that 562 
had Pvalue significance levels at metaanalysis < 1004. Three SNPs in loci not previously 563 
reported as associated with SLE had genome wide level of significance (P < 5 × 1008) after 564 
metaanalysis. SNPs spanning a 1Mb window were considered as one region and we 565 
selected only independent SNPs within this region: using LD as a measure of independence. 566 
We performed a genebased test on the metaanalyzed data, using only SNPs that passed 567 
INFO > 0.9, applying the software KGG39-41. One SNP from each of the loci that passed a 568 
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gene based test at the level of P < 1005 were chosen, some of which were already selected 569 
as having P < 1004 in the metaanalysis as single markers. In total 105 SNPs were selected 570 
for replication in the Chinese replication cohort. From these 66 passed QC and 18 SNPs, 571 
that passed a FDR < 1%, were taken forward to a further replication in the European 572 
replication. 573 
Genotyping of replication data 574 
Genotyping of 130 SNPs was performed in 3,614 cases and 5,924 controls forming the 575 
Chinese replication set, using the Sequenom platform. This set of 130 SNPs included 105 576 
SNPs in loci not previously reported as associated with SLE and 25 SNPs that were in loci 577 
that had previously been published as associated with SLE. The 105 potentially novel SNPs 578 
included, in some cases, multiple SNPs in the same loci where we had some evidence of 579 
independence. Several quality control (QC) steps were performed. SNPs with >10% missing 580 
data were removed (25 SNPs) followed by subjects with >5% missing data being removed.  581 
Two SNPs were monomorphic. Of the remaining 103 SNPs, 77 were in regions of the 582 
genome with potentially novel SLE associations. Thirteen SNPs were removed after 583 
checking the genotyping allele intensity plots closely for clustering quality and testing for 584 
Hardy Weinberg Equilibrium (HWE). SNPs were removed if HWE P < 1.00 × 1004.  Post-QC 585 
the Chinese replication consisted of 3,043 cases, 5,074 controls with genotyping on 64 586 
SNPs. The European replication data comprised 1,478 cases and 6,925 controls genotyped 587 
for 18 SNPs that passed a False Discovery Rate of 1% in the Chinese replication study: the 588 
cases were of European ancestry and were a subset of those used in the replication study in 589 
the European GWAS3, on which this current study performed new genotyping on these 18 590 
SNPs, and the controls were the same as used in that study (these samples were checked 591 
for European ancestry using a principal component analysis spiked with HapMap samples, 592 
see original paper). One of the 18 SNPs typed in the European replication cohort for this 593 
study (rs2297550) failed genotyping and the remaining 17 SNPs passed QC (< 3% missing 594 
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data, HWE P > 1.00 × 1004). An additional European GWAS was also used for replication, 595 
comprising 1,165 cases and 2,107 controls15. 596 
Gene expression data 597 
Gene expression data were obtained from two sources: firstly, we obtained data from Fairfax 598 
et al17 and unpublished data from Fairfax and Knight for NK cells, naïve monocytes, 599 
monocytes stimulated by LPS (harvested after 2 hours and 24 hours), monocytes stimulated 600 
by IFN and B cells. The CD4 (CD4 T cells) and CD14 (CD14/16 monocytes) data were 601 
obtained from a previous study of gene expression in immune related cells16. An adjustment 602 
was made for multiple testing using a false discovery rate at 0.01. To test whether observed 603 
associations between SNPs and expression levels of cis-acting genes were due to chance, 604 
we calculated the RTC score18.  605 
Fine mapping Bayesian credibility sets. 606 
For each of the associated loci in Supplementary Table 1 and Table 1, we calculated a 607 
Bayes factor for each SNP within the 2Mb window. We used the approximate Bayes factor of 608 
Wakefield32. We then calculated the posterior probability that each SNP was driving the 609 
association, using the Bayes factors, and created credibility sets as recently described32. We 610 
created credibility sets using the European data and the Chinese data separately and 611 
overlaid these sets (presented in Supplementary Fig 5). We focused on the intersection of 612 
these two sets and present the SNPs with highest posterior probability within this 613 
intersection along with allele frequencies. We focus on the intersection of the two 614 
populations sets, as credibility sets calculated from the overall metaanalysis are driven by 615 
the European data. This would also be true if we were to use Bayesian updating (where the 616 
posterior probabilities from one population were used as priors in the other population). The 617 
intersection of the sets gives a subset of each populations C.S. that more likely contain the 618 
true casual SNP. 619 
RoadMap Data 620 
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We downloaded the epigenetic data for SNPs within the credibility intervals (as defined in 621 
Supplementary Fig. 5) around each meta-analysis SNP (Table 1) from the RoadMap 622 
consortium for all blood cell types. We chose DNse, RNA-Seq, H3K27ac (distinguishing 623 
active enhancers/promoters), H3K27me3 (repressive domains), H3K9ac (promoters), 624 
H3K9me3 (constitutive heterochromatin). The files downloaded contained the consolidated 625 
imputed epigenetic data based on the P-value signals from each of the individual epigenetic 626 
marks in each of the cell types within whole blood.  We used the UCSC genome browser 627 
(hg19) to subset each epigenetic track for regions containing each credibility SNP and then 628 
exported the signal data via Galaxy42. In selecting chromatin enrichments at each mark for 629 
each SNP within the credibility set, we ensured that no SNP was less than 10 bp away from 630 
the edge of the 25 base pair epigenetic interval containing it.  For SNPs closer to the edge of 631 
the chromatin interval, we averaged the enrichment from two adjacent intervals. The 3D 632 
enrichment diagrams were plotted for each chromatin mark in each cell type for each SNP 633 
within the credibility set (Fig. 3 and Supplementary Fig. 6).  Fig. 3 and Supplementary Fig. 6 634 
highlight SNPs contained within peaks of enrichment (log10 P < 1 x 1004) with tick marks, 635 
these SNPs are listed in Supplementary Table 6. 636 
Genetic structure of SLE in European and Asian population 637 
The genetic risk score was calculated according to the method described by Hughes et al.43, 638 
taking the number of risk alleles (i.e., 0, 1 or 2) for a given SNP and multiplying it by the 639 
natural log of its odds ratio (OR). The cumulative risk score in each subject was calculated 640 
by summing the risk scores from the loci in Supplementary Table 1, excluding the MHC, plus 641 
the 11 novel SNPs reported in this paper, which robustly associated with SLE and passed 642 
quality control in each population: 643 
ܥݑ݉ݑ݈ܽݐ݅ݒ݁݃݁݊݁ݐ݅ܿݎ݅ݏ݇ݏܿ݋ݎ݁ ൌ෍݈݊ሺܱܴ௜ሻܩ௜௠௜ୀଵ  
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Where m represents number of SLE risk loci; ܱܴ௜ indicates the OR of risk SNPi and ܩ is the 644 
number of risk alleles at a given SNP. Cumulative risk scores were calculated for 498 645 
founders in EUR, 503 founders in EAS, 487 in SAS, 347 in AMR and 657 in AFR from the 646 
1KG project phase III. We tested for differences in GRS using a t-test. A Q-Q plot for each 647 
data satisfied assumptions of normality and given the large sample sizes the central limit 648 
theorem will satisfy normality for the distribution of sample means. As there was evidence of 649 
differences in variances of the GRS between some pairs of populations (EUR vs AMR, P = 650 
9.97 x 1005; AMR vs SAS, P = 5.37 x 1005 SAS vs EAS, P = 4.50 x 1003), we used a Welch 651 
2-sample t-test which does not assume equal variances. The variances in each group were 652 
as follows (Chinese controls = 0.75, European Controls = 0.69; 1KG EAS = 0.86, 1KG EUR 653 
= 0.67, 1KG SAS = 0.66, 1KG AMR = 0.99, 1KG AFR = 0.77). We used the SNPs from 654 
Supplementary Table 1a to calculate the GRS for each population. We used the estimated 655 
OR from the EUR GWAS for the calculation of the GRS in Europeans (EUR and GWAS 656 
controls) and the OR from the Chinese GWAS for the calculation of the GRS in the EAS and 657 
Chinese GWAS controls. The OR from the EUR-Chinese meta-analysis was used in 658 
calculating the GRS in the AMR, SAS and AFR populations. 659 
See supplementary note 1 for an assessment of the robustness of our approach.  660 
See supplementary note 2 for details on SLE prevalence.  661 
Heritability explained  662 
We calculated the heritability explained by all genotyped SNPs in the CHN and EUR 663 
populations using GCTA44. We assumed that the Chinese have approximately 3 fold 664 
increase in prevalence over the Europeans, so we set the prevalence at 0.0003 in EUR and 665 
0.001 in CHN. We used a cut off for relatedness at 0.05 and we used sex as a covariate. 666 
The results were h2=28.4% (SE = 2.6%) in CHN and h2=27.0% (SE = 1.0%) in EUR for 667 
autosomal SNPs. We found that the results were robust to choice of relatedness for the 668 
autosomal SNPs [a cut-off of 0.125 resulted in h2=28.4% (SE = 2.6%) in CHN and h2=27% 669 
27 
 
(SE = 1.0%) in EUR] while not so for the X chromosome [a cut-off of 0.125 resulted in 670 
h2=1.2% (SE = 0.5%) in CHN and h2=1.1% (SE = 0.2%) in EUR] where a cut-off for 671 
relatedness at 0.05 resulted in h< 0.015 in both populations.   672 
To compare both populations using the same SNP density we re-ran the analysis on the 673 
overlap of genotyped SNPs (267,005 SNPs with MAF > 1% in CHN and 264,833 with MAF > 674 
1% in EUR) and find that the heritability explained was higher in the CHN data: h2=30.2% 675 
(SE = 2.6%) in CHN and h2=22.7% (SE = 0.9%) in EUR.  676 
Genetic correlation between European and Chinese SLE GWAS 677 
To estimate genetic correlation (rg) we applied LD score regression
34 to the summary 678 
association data in the European GWAS and the meta-analysis of the Chinese data (the 679 
input data is all GWAS summary statistics not just the SLE risk loci discussed in this paper). 680 
While this methodology is designed to compare similarity of genetic risk across diseases in 681 
the same population it serves here only to illustrate similarity across populations for the 682 
same disease and to highlight the heterogeneity at the MHC. We performed this analysis 683 
using both Asian (rg =0.49, P = 3.00 x 1003) and European (rg=0.51, P = 4.00 x 1003) 684 
reference LD information. This analysis was performed using summary data on all the SLE 685 
risk loci presented in this paper and a further analysis after removing the MHC [Asian (rg 686 
=0.63, P = 6.92 x 1007) and European (rg =0.62, P = 4.88 x 1005)]. The increase in rg post 687 
removal of the MHC illustrates the major heterogeneity at this locus.   688 
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